# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001062993-26-002371
**Filing Date:** 2026-5
**Character Count:** 19156
**Document Hash:** a9e49ecafa3756d38bc0dc11eefc0fd6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-26-002371.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001062993-26-002371

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260506

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 26950081

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

?xml version='1.0' encoding='ASCII'? InMed Pharmaceuticals Inc.: Form 8-K - Filed by newsfilecorp.com

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**___________________________**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):  **<u>May 6, 2026</u>**

**<u>INMED PHARMACEUTICALS INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
|  **<u>British Columbia</u>** |  **<u>001-39685</u>** |  **<u>98-1428279</u>** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Suite 1445 – 885 West Georgia Street <u>Vancouver, British Columbia, Canada V6C 3E8</u>** (Address of principal executive offices) (ZIP Code)

Company's telephone number, including area code: **<u>(604) 669-7207</u>**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbols** | **Name of each exchange on which registered** |
| Common Shares, no par value | INM | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

On May 6, 2026, the Company reported financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01.**

**Financial Statements and Exhibits.** 

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| [99.1](exhibit99-1.htm) | [News release, dated May 6, 2026](exhibit99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | INMED PHARMACEUTICALS INC. | INMED PHARMACEUTICALS INC. |
| Date: May 6, 2026 | By: | /s/ Eric A Adams |
|  |  | Eric A Adams<br>President & CEO |

---

------

## Exhibit 99.1

------

---

| | |
|:---|:---|
| ![](exhibit99-1x001.jpg) | **NASDAQ: INM**<br>Suite 1445-885 West Georgia St.<br>Vancouver, BC, Canada V6C 3E8<br>Tel: +1.604.669.7207<br>Email: info@inmedpharma.com<br>www.inmedpharma.com |

---

**InMed Reports Third Quarter Fiscal 2026 Financial Results and <br>Provides Business Update**

Vancouver, BC - May 6th, 2026 - InMed Pharmaceuticals Inc. ("**InMed**" or the "**Company**") (**Nasdaq: INM**), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026.

The Company's full financial statements and related MD&A for the third quarter ended March 31, 2026, are available at <u>www.inmedpharma.com</u>, <u>www.sedarplus.com</u> and at <u>www.sec.gov</u>.

"During the quarter, InMed reported additional preclinical data that further support the development of INM-901 for Alzheimer's disease through its targeting of neuroinflammation. Data from advanced human brain organoid systems demonstrated anti-neuroinflammatory effects consistent with findings observed across multiple *in vivo* and *ex vivo* studies," commented Eric A. Adams, InMed President and CEO.

<u>**Business Update**</u>

**INM-901: Targeting the Modulation of Neuroinflammation in Alzheimer's disease**<br>InMed's proprietary, disease-modifying, small molecule drug candidate INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and continues to advance as a potential treatment for Alzheimer's disease with a primary focus on modulating neuroinflammation. During the quarter, InMed announced preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease.

The *in vitro* human organoid models represent some of the closest approximations to human brain tissue currently available, incorporating a complex cellular environment relevant to neurodegenerative disease. The organoids are composed of neurons, astrocytes, vascular cells and feature microglia, the brain's resident immune cells, and can be used to bridge the gap between traditional animal models and human clinical trials.

INM-901 was evaluated in two distinct human 3D organoid models: a general model of neuroinflammation induced with lipopolysaccharide ("LPS") and interferon-gamma ("IFN-γ"); and, Stem Pharm's proprietary neuroinflammation Alzheimer's disease model with specific features observed in Alzheimer's disease patients.

**Key Observations included:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Effects align with prior findings from an *in vivo* Alzheimer's model and an *ex vivo* LPS-induced neuroinflammation model.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Provides supportive evidence of mechanistic translation from animal models to human tissue systems.

The consistency of INM-901's anti-inflammatory effects across *in vivo* animal models, *ex vivo* systems and now human 3D brain organoids provide increasing confidence in the compound's potential to translate into clinical benefit in humans with neuroinflammatory conditions.

**Discontinued Operations**

On March 4, 2026, the Company's board of directors ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica's commercial operations business segment ("Commercial Operations"), which is the only revenue-generating commercial operations of the Company. BayMedica intends to substantially complete the wind down and exit prior to the end of its fiscal year ending June 30, 2026. During the interim period leading to the completion of operational wind down, BayMedica will continue its commercial operations including sales, marketing, limited manufacturing, and logistics.

<u>**Financial Commentary**</u>

Following the classification of the Commercial segment as discontinued operations, the Company has one reportable segment that constitutes consolidated results consisting of its operations. Unless otherwise noted, all activities and amounts reported in the following notes relate to the continuing operations of the Company and exclude activities and amounts related to discontinued operations.

For the three months ended March 31, 2026, the Company reported a net loss of $3.0 million, compared to a net loss of $2.1million in the same period the previous year. The increase was largely driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs.

Pharmaceutical research and development for continuing operations were $1.0 million for the three months ended March 31, 2026, compared with $0.4 million for the three months ended March 31, 2025. The increase was primarily due to an increase in external contractors relating to our INM-901 program

General and administrative expenses for continuing operations were $1.7 million for the three months ended March 31, 2026, compared to $1.6 million the same period the previous year. The increase resulted primarily from a combination of changes including lower accounting fees, share-based payments fees, and shareholder communication fees.

As of March 31, 2026, the Company's cash, cash equivalents and short-term investments were $5.2 million, which compares to $10.8 million on June 30, 2025.

The Company reported no revenue from continuing operations for the period. The discontinued commercial operations generated revenue of $0.7 million during the period; however, its results are classified as discontinued operations and are presented separately from continuing operations.

------

**Table 1. Consolidated Balance Sheet**<br>Expressed in U.S. Dollars

---

| |
|:---|
| **ASSETS** |
| **Current** |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents |
| &nbsp;&nbsp;&nbsp;Short-term investments |
| &nbsp;&nbsp;&nbsp;Prepaids and other current assets |
| &nbsp;&nbsp;&nbsp;Current assets of discontinued operations |
| Total current assets |
| **Non-Current** |
| &nbsp;&nbsp;&nbsp;Property, equipment and ROU assets, net |
| &nbsp;&nbsp;&nbsp;Intangible assets, net |
| &nbsp;&nbsp;&nbsp;Other assets |
| **Total Assets** |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |
| **Current** |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities |
| &nbsp;&nbsp;&nbsp;Current portion of lease obligations |
| &nbsp;&nbsp;&nbsp;Current liabilities of discontinued operations |
| Total current liabilities |
| **Non-current** |
| &nbsp;&nbsp;&nbsp;Lease obligations, net of current portion |
| **Total Liabilities** |
| **Commitments and Contingencies (Note 9)** |
| **Shareholders' Equity** |
| Common shares, no par value, unlimited authorized shares: 3,314,063 and 2,002,186 as of March 31, 2026 and June 30, 2025, respectively, issued and outstanding |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital |
| &nbsp;&nbsp;&nbsp;Accumulated deficit**)** |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income |
| **Total Shareholders' Equity** |
| **Total Liabilities and Shareholders' Equity** |

---

------

**Table 2. Consolidated Statements of Operations**<br>Expressed in U.S. Dollars

---

| |
|:---|
| **Operating Expenses** |
| &nbsp;&nbsp;&nbsp;Research and development |
| &nbsp;&nbsp;&nbsp;General and administrative |
| &nbsp;&nbsp;&nbsp;Amortization and depreciation |
| &nbsp;&nbsp;&nbsp;Foreign exchange loss |
| Total operating expenses |
| **Other Income (Expense)** |
| &nbsp;&nbsp;&nbsp;Interest and other income |
| &nbsp;&nbsp;&nbsp;Finance expense) |
| **Net loss from continuing operations before taxes))**) |
| Income tax expense |
| **Net loss from continuing operations))**) |
| Discontinued operations: |
| Income (Loss) from discontinued operations |
| Income tax benefit |
| Loss from discontinued operations) |
| Net Loss)) |
| **Net loss per share for the period** |
| &nbsp;&nbsp;&nbsp;Basic and diluted: |
| &nbsp;&nbsp;&nbsp;Continuing operations**))** |
| &nbsp;&nbsp;&nbsp;Discontinued Operations**))** |
| &nbsp;&nbsp;&nbsp;Net loss per share attributable to Common Stockholders - basic and diluted**))**) |
| **Weighted average outstanding common shares** |
| &nbsp;&nbsp;&nbsp;**Basic and diluted** |

---

------

**Table 3. Consolidated Statements of Cash Flows**<br>Expressed in U.S. Dollars

---

| |
|:---|
| **Cash provided by (used in):** |
| **Operating Activities** |
| Net loss**)** |
| Items not requiring cash: |
| &nbsp;&nbsp;&nbsp;Amortization and depreciation |
| &nbsp;&nbsp;&nbsp;Share-based compensation |
| &nbsp;&nbsp;&nbsp;Amortization of right-of-use assets |
| &nbsp;&nbsp;&nbsp;Unrealized foreign exchange loss |
| Changes in operating assets and liabilities: |
| &nbsp;&nbsp;&nbsp;Prepaids and other currents assets**)** |
| &nbsp;&nbsp;&nbsp;Other non-current assets**)** |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities**)** |
| &nbsp;&nbsp;&nbsp;Lease obligations**)** |
| &nbsp;&nbsp;&nbsp;Operating cash flow used by discontinued operations |
| **Total cash used in operating activities)**) |
| **Investing Activities** |
| &nbsp;&nbsp;&nbsp;Sale of short-term investments |
| &nbsp;&nbsp;&nbsp;Purchase of short-term investments**)**) |
| **Total cash used in investing activities** |
| **Financing Activities** |
| &nbsp;&nbsp;&nbsp;Proceeds from the private placement |
| &nbsp;&nbsp;&nbsp;Share issuance costs**)**) |
| **Total cash provided by financing activities** |
| **Decrease in cash and cash equivalents during the period)** |
| **Cash and cash equivalents beginning of the period** |
| **Cash and cash equivalents end of the period** |
| **SUPPLEMENTARY CASH FLOW INFORMATION:** |
| &nbsp;&nbsp;&nbsp;Cash paid during the period for: |
| &nbsp;&nbsp;&nbsp;Income taxes |
| &nbsp;&nbsp;&nbsp;Interest |
| **SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:** |
| Recognition of Right-of-use asset and corresponding operating lease |

---

------

**About InMed**

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

**Investor Contact:** 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: <u>ir@inmedpharma.com</u>

**Cautionary Note Regarding Forward-Looking Information:**

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on <u>www.sec.gov</u>.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

------